Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome.

Abstract

OBJECTIVES:

To determine the neuropathological load in the living brain of nondemented adults with Down syndrome using positron emission tomography with 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) and to assess the influence of age and cognitive and behavioral functioning. For reference, [(18)F]FDDNP binding values and patterns were compared with those from patients with Alzheimer disease and cognitively intact control participants.

DESIGN:

Cross-sectional clinical study.

PARTICIPANTS:

Volunteer sample of 19 persons with Down syndrome without dementia (mean age, 36.7 years), 10 patients with Alzheimer disease (mean age, 66.5 years), and 10 controls (mean age, 43.8 years).

MAIN OUTCOME MEASURES:

Binding of [(18)F]FDDNP in brain regions of interest, including the parietal, medial temporal, lateral temporal, and frontal lobes and posterior cingulate gyrus, and the average of all regions (global binding).

RESULTS:

The [(18)F]FDDNP binding values were higher in all brain regions in the Down syndrome group than in controls. Compared with the Alzheimer disease group, the Down syndrome group had higher [(18)F]FDDNP binding values in the parietal and frontal regions, whereas binding levels in other regions were comparable. Within the Down syndrome group, age correlated with [(18)F]FDDNP binding values in all regions except the posterior cingulate, and several measures of behavioral dysfunction showed positive correlations with global, frontal, parietal, and posterior cingulate [(18)F]FDDNP binding.

CONCLUSIONS:

Consistent with neuropathological findings from postmortem studies, [(18)F]FDDNP positron emission tomography shows high binding levels in Down syndrome comparable to Alzheimer disease and greater levels than in members of a control group. The positive associations between [(18)F]FDDNP binding levels and age as well as behavioral dysfunction in Down syndrome are consistent with the age-related progression of Alzheimer-type neuropathological findings in this population.

• Authors: Linda D Nelson, Prabha Siddarth, Vladimir Kepe, Kevin E Scheibel, S C Huang, Jorge R Barrio, Gary W Small
• Journal: Archives of neurology (Arch Neurol) Vol. 68 Issue 6 Pg. 768-74 (Jun 2011) ISSN: 1538-3687 [Electronic] United States
• PMID: 21670401 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Amyloid beta-Peptides
• tau Proteins

Topics

• Adult
• Aged
• Alzheimer Disease (diagnostic imaging, metabolism, pathology)
• Amyloid beta-Peptides (metabolism)
• Cross-Sectional Studies
• Down Syndrome (diagnostic imaging, metabolism, pathology)
• Female
• Humans
• Male
• Middle Aged
• Plaque, Amyloid (diagnostic imaging, metabolism, pathology)
• Positron-Emission Tomography (methods)
• Protein Binding
• Young Adult
• tau Proteins (metabolism)